IQ EQ FUND MANAGEMENT IRELAND Ltd Acquires 9,472 Shares of Natera, Inc. $NTRA

IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its position in Natera, Inc. (NASDAQ:NTRA) by 134.5% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 16,516 shares of the medical research company’s stock after buying an additional 9,472 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in Natera were worth $2,790,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Bank of Jackson Hole Trust purchased a new position in shares of Natera in the 1st quarter worth approximately $29,000. TCTC Holdings LLC boosted its stake in Natera by 114.8% in the 1st quarter. TCTC Holdings LLC now owns 232 shares of the medical research company’s stock worth $33,000 after purchasing an additional 124 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its stake in Natera by 83.5% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company’s stock worth $33,000 after purchasing an additional 106 shares in the last quarter. Hilltop National Bank acquired a new stake in Natera in the 2nd quarter worth approximately $33,000. Finally, Oliver Lagore Vanvalin Investment Group acquired a new stake in Natera in the 2nd quarter worth approximately $36,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Price Performance

Shares of NASDAQ:NTRA opened at $192.22 on Tuesday. Natera, Inc. has a 1 year low of $117.27 and a 1 year high of $198.99. The firm has a market capitalization of $26.38 billion, a price-to-earnings ratio of -100.64 and a beta of 1.74. The business’s 50 day moving average price is $171.92 and its 200-day moving average price is $160.71.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The firm had revenue of $546.60 million during the quarter, compared to analyst estimates of $476.84 million. During the same quarter in the previous year, the firm posted ($0.30) earnings per share. The company’s quarterly revenue was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Analyst Ratings Changes

NTRA has been the subject of a number of recent analyst reports. Evercore ISI upgraded shares of Natera to a “strong-buy” rating and set a $170.00 target price for the company in a research note on Monday, July 28th. Stephens reiterated an “overweight” rating and issued a $183.00 target price on shares of Natera in a research note on Friday, August 15th. Piper Sandler reiterated an “overweight” rating and issued a $220.00 target price (up from $210.00) on shares of Natera in a research note on Monday, August 11th. Canaccord Genuity Group reissued a “buy” rating and set a $200.00 price target on shares of Natera in a research report on Tuesday, October 14th. Finally, Barclays reissued an “overweight” rating and set a $210.00 price target (up from $190.00) on shares of Natera in a research report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $194.89.

Insider Transactions at Natera

In related news, CFO Michael Burkes Brophy sold 2,491 shares of the stock in a transaction on Tuesday, September 30th. The stock was sold at an average price of $162.05, for a total value of $403,666.55. Following the completion of the transaction, the chief financial officer directly owned 69,189 shares of the company’s stock, valued at approximately $11,212,077.45. This represents a 3.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Rowan E. Chapman sold 2,750 shares of the stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $166.99, for a total value of $459,222.50. Following the completion of the transaction, the director directly owned 6,015 shares of the company’s stock, valued at approximately $1,004,444.85. This represents a 31.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 57,374 shares of company stock worth $9,108,022 in the last quarter. 5.63% of the stock is owned by insiders.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.